Generic Medicine Info
Indications and Dosage
Hodgkin's disease
Adult: Monotherapy: Initially, 50 mg/day, increased by 50 mg daily to 250-300 mg daily in divided doses. Continue doses until max response is achieved or appearance of signs of toxicity. Maintenance: 50-150 mg/day or 1-2 mg/kg daily until a cumulative dose of at least 6 g. Combination Therapy: 100 mg/m2 on days 1-14 of each 4- or 6-wk cycle.
Child: Initially, 50 mg/m2 daily, up to 100 mg/m2 adjust according to response.
Pregnancy. Lactation. Myelosuppression. Severe hepatic and renal impairment.
Special Precautions
May increase blood glucose in diabetics. Monitor peripheral blood counts regularly. Monitor hepatic and renal function wkly. Pheochromocytoma, epilepsy, CV or cerebrovascular disease., hepatic or renal impairment Discontinue use if hypersensitivity occurs.
Adverse Reactions
GI disturbances, anorexia, nausea and vomiting; bone marrow depression; leukopenia and thrombocytopaenia; anaemia, haemolysis and bleeding tendencies; neurotoxicity, lethargy, ataxia and sleep disorders. Fever, myalgia, pulmonary fibrosis or pneumonitis, haematuria, urinary frequency, skin reactions, tachycardia, orthostatic hypotension, ocular defects, infertility and hepatic impairment.
Drug Interactions
Increased risk of hypersensitivity reactions when used with enzyme-inducing antiepileptics. Potentiation of sedative effects with CNS depressants. Increased risk of agranulocytosis with clozapine. Disulfiram-like reaction with alcohol. May enhance the anithypertensive effects of antihypertensive agents.
Description: Procabazine, an alkylating agent, damages DNA, inhibits DNA, RNA and protein synthesis. It is able to block the MAO action in the CNS. It is not cross-resistant with other alkylating agents and is S-phase specific.
Absorption: Readily absorbed from the GI tract.
Distribution: Crosses the blood-brain barrier and diffuses into the CSF.
Metabolism: Rapidly metabolised mainly in the liver and kidneys.
Excretion: About 5% excreted unchanged in urine.
Protect from light.
Disclaimer: This information is independently developed by MIMS based on Procarbazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in